keyword
MENU ▼
Read by QxMD icon Read
search

Uterine papillary serous cancer

keyword
https://www.readbyqxmd.com/read/27759595/survival-differences-among-uterine-papillary-serous-clear-cell-and-grade-3-endometrioid-adenocarcinoma-endometrial-cancers-a-national-cancer-database-analysis
#1
Mary McGunigal, Jerry Liu, Tamara Kalir, Manjeet Chadha, Vishal Gupta
OBJECTIVES: High-risk histology including UPSC, CC, and high-grade (G3) endometrioid adenocarcinoma (EAC) have a worse prognosis compared to G1-2 EAC. It is unknown whether G3EAC outcomes are more similar to UPSC/CC or to G1-2 EAC. The purpose of this study was to compare overall survival (OS) among UPSC, CC, and G1-3 EAC, for International Federation of Gynecology and Obstetrics stages I to III. METHODS: The National Cancer Data Base was queried for patients diagnosed with International Federation of Gynecology and Obstetrics (1988 classification) Stage I-III UPSC, CC, and EAC from 1998 to 2012 who underwent surgery as definitive treatment...
October 18, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27672676/metastatic-papillary-serous-uterine-cancer-presenting-as-a-rash
#2
Eric S Chang, William D Baker, Charles N Landen
BACKGROUND: We report diagnosis and management of stage IV papillary serous uterine cancer with initial clinical presentation as a skin rash. CASE: A 62-year-old postmenopausal female developed an erythematous rash beginning on her right lower abdomen and progressively spreading to her left abdomen, vulva, and neck. After a trial of antibiotic treatment, biopsy of left neck and right thigh skin nodules revealed papillary serous carcinoma. Abdominopelvic tomography revealed endometrial thickening and a 5 cm left adnexal mass...
November 2016: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/27539290/comparison-of-the-classical-method-and-see-fim-protocol-in-detecting-microscopic-lesions-in-fallopian-tubes-with-gynecological-lesions
#3
Nermin Koc, Selçuk Ayas, Sevcan Arzu Arinkan
Background: The objective of this study was to compare the classical method and Sectioning and Extensively Examining the Fimbriated End Protocol (SEE-FIM) in detecting microscopic lesions in fallopian tubes with gynecological lesions. Materials and Methods: From a total of 1,118 cases, 582 with various parts of both fallopian tubes sampled in three-ring-shape sections and 536 sampled with the SEE-FIM protocol were included in this study. Pathological findings of cases with endometrial carcinoma, non-uterine pelvic malignant tumor, ovarian borderline tumors, premalignancy, and benign lesions were compared...
August 19, 2016: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/27514313/analysis-of-clinical-and-pathological-characteristics-treatment-methods-survival-and-prognosis-of-uterine-papillary-serous-carcinoma
#4
Ulas Solmaz, Atalay Ekin, Emre Mat, Cenk Gezer, Askin Dogan, Alper Biler, Nuri Peker, Pinar Solmaz Hasdemir, Muzaffer Sanci
PURPOSE: Uterine papillary serous carcinoma (UPSC) is an atypical variant of endometrial carcinoma with a poor prognosis. It is commonly associated with an increased risk of extrauterine disease. The aim of this study was to investigate clinical and pathological characteristics, therapeutic methods, and prognostic factors in women with UPSC. METHODS: All patients who underwent surgery for UPSC at a single high-volume cancer center between January 1995 and December 2010 were retrospectively reviewed...
August 4, 2016: Tumori
https://www.readbyqxmd.com/read/27426853/hormone-therapy-after-prophylactic-risk-reducing-bilateral-salpingo-oophorectomy-in-women-who-have-brca-gene-mutation
#5
F Guidozzi
Women with a BRCA1 or BRCA2 gene mutation have substantially higher risk for developing not only breast and ovarian cancers, but also for primary peritoneal, Fallopian tube, colonic, pancreatic cancers, uterine papillary serous adenocarcinoma and malignant melanoma. The risk for ovarian cancer ranges from 39 to 49% by 70 years of age in BRCA1 mutation carriers and from 11 to 18% for those with a BRCA2 mutation, whilst breast cancer increases similarly within women who have either the BRCA1 mutation or the BRCA2 mutation, from about 20% in women in their forties, 37% by the age of 50 years, 55% by 60 years and more than 70% by the age of 70 years...
October 2016: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/27352560/detection-and-correlation-of-pre-operative-frozen-section-and-final-pathology-in-high-risk-endometrial-cancer
#6
M J Kanis, J Rahaman, E L Moshier, K Zakashansky, L Chuang, V Kolev
PURPOSE: To evaluate sensitivity and specificity of pre-operative and frozen section pathologic evaluation (FSA) in predicting high-risk (HR) histology endometrial cancer. MATERIALS AND METHODS: A retrospective analysis was performed on all patients diagnosed with endometrial cancer at a single institution. Medical records were abstracted for baseline characteristics, surgical reports for staging, and final histology was confirmed by a gynecologic pathologist. RESULTS: 868 patients were identified...
2016: European Journal of Gynaecological Oncology
https://www.readbyqxmd.com/read/27266220/comparative-survival-outcomes-of-uterine-papillary-serous-carcinoma-clear-cell-carcinoma-grade-3-endometrioid-adenocarcinoma-and-carcinosarcoma-of-endometrial-cancer-in-rajavithi-hospital
#7
COMPARATIVE STUDY
Nisa Prueksaritanond, Wasu Chantape
BACKGROUND: Uterine papillary serous carcinoma (UPSC), clear cell carcinoma (CC), grade 3 endometrioid adenocarcinoma (G3EC), and carcinosarcoma (CS) have been identified as high-grade endometrial cancers and account for the majority of uterine cancer deaths. OBJECTIVE: To compare survival outcomes of patients with UPSC, CC, G3EC and CS in Rajavithi Hospital. MATERIAL AND METHOD: A retrospective review was performed of all patients with FIGO stage I-IV endometrial cancer in Rajavithi Hospital between 1 January 2007 and 31 December 2012...
February 2016: Journal of the Medical Association of Thailand, Chotmaihet Thangphaet
https://www.readbyqxmd.com/read/27117594/adrenal-metastasis-from-uterine-papillary-serous-carcinoma
#8
Sandeep Singh Lubana, Navdeep Singh, Sandeep S Tuli, Barbara Seligman
BACKGROUND: Uterine papillary serous carcinoma (UPSC) is a highly malignant form of endometrial cancer with a high propensity for metastases and recurrences even when there is minimal or no myometrial invasion. It usually metastasizes to the pelvis, retroperitoneal lymph nodes, upper abdomen, and peritoneum. However, adrenal metastases from UPSC is extremely rare. Here, we present a case of UPSC with adrenal metastasis that occurred 6 years after the initial diagnosis. CASE REPORT: A 60-year-old woman previously diagnosed with uterine papillary serous carcinoma at an outside facility presented in September of 2006 with postmenopausal bleeding...
2016: American Journal of Case Reports
https://www.readbyqxmd.com/read/27083603/-s028-is-there-a-difference-in-survival-between-patients-with-uterine-papillary-serous-clear-cell-and-grade-3-endometrial-cancers-a-national-cancer-data-base-analysis
#9
(no author information available yet)
No abstract text is available yet for this article.
April 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/27048103/adjuvant-therapy-for-stage-ia-uterine-clear-cell-carcinoma-with-no-myometrial-invasion-a-critical-review-of-literature
#10
REVIEW
G A Desteli, N U Dogan, T Gursu, A Ayhan
Uterine clear cell carcinoma (UCC) is an aggressive variant of endometrial cancer. Comprehensive surgical staging is strongly recommended for these patients as an upstaging to Stage 3-4 occur in 35-50% of patients. Stage 1A (no myometrial invasion) according to FIGO 1988 staging system are seen very rarely in patients. In most of the studies, regarding adjuvant treatment, clear cell carcinoma were all evaluated with papillary serous carcinoma (PSC). Studies on clear cell histology are low in number and also a limited number of patients were included...
2016: European Journal of Gynaecological Oncology
https://www.readbyqxmd.com/read/27028349/adjuvant-pelvic-radiation-therapy%C3%A2-vaginal-brachytherapy-in-patients-with-high-risk-stage-i-or-stage-ii-uterine-papillary-serous-clear-cell-and-high-grade-endometrioid-carcinoma
#11
Himanshu Nagar, Weisi Yan, Bhupesh Parashar, Dattatreyudu Nori, K S C Chao, Paul Christos, Divya Gupta, Kevin Holcomb, Thomas Caputo, A Gabriella Wernicke
PURPOSE: Radiation therapy (RT) for stages I-II uterine papillary serous carcinoma (UPSC), clear cell (CC), and high-grade endometrioid (HGE) carcinoma present a treatment challenge. Regimens include external beam radiotherapy (EBRT) with or without brachytherapy. We examine the use of these radiation modalities in these endometrial cancers (EC) with respect to cause-specific survival (CSS). METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was queried for patients with AJCC stages I-II UPSC, CC, or HGE cancer treated with hysterectomy and RT between 1998 and 2008...
August 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26950465/early-stage-uterine-pure-and-mixed-clear-cell-carcinoma-outcomes-and-recurrence-with-and-without-adjuvant-therapy
#12
Christine N Chang-Halpenny, Sathima Natarajan, Julie M Hwang-Graziano
OBJECTIVE: Clear cell carcinoma (CCC) of the uterus is a rare but aggressive histology for which the role of adjuvant therapy for stage I-II disease is unclear. Our study investigated outcomes and patterns of failure in these patients. METHODS: We found 64 cases of CCC, including 26 of pure CCC, 22 mixed with endometrioid adenocarcinoma, and 16 mixed with uterine papillary serous carcinoma. Adjuvant treatment was given to 55%. RESULTS: Median follow-up was 51...
March 4, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26894377/the-prognostic-significance-of-hematological-parameters-in-women-with-uterine-serous-papillary-carcinoma-uspc
#13
Grace Younes, Yakir Segev, Julia Begal, Ron Auslender, Yael Goldberg, Amnon Amit, Ofer Lavie
OBJECTIVES: Preoperative hematologic parameters: thrombocytosis, leukocytosis and anemia have been demonstrated to be independent poor prognostic factors in ovarian and endometrial cancers. However, little is known about their relation to uterine serous papillary carcinoma (USPC). We evaluated several preoperative hematologic parameters and their association with clinicopathologic features, disease progression and overall survival in USPC patients. STUDY DESIGN: This was a retrospective cohort study reviewing charts of all patients with a histologic pure USPC at two gynecologic oncology centers from January 2000 through July 2012...
April 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/26763061/singapore-cancer-network-scan-guidelines-for-the-systemic-therapy-of-endometrial-uterine-cancer
#14
(no author information available yet)
INTRODUCTION: The SCAN gynaecological cancers systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for the systemic therapy of endometrial (uterine) cancer. MATERIALS AND METHODS: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. RESULTS: Three international guidelines were evaluated- those developed by the National Cancer Comprehensive Network (2015), the European Society of Medical Oncology (2013) and the Cancer Council Australia (2011)...
October 2015: Annals of the Academy of Medicine, Singapore
https://www.readbyqxmd.com/read/26588230/uterine-papillary-serous-carcinoma-a-single-institution-review-of-62-cases
#15
Carin Black, Amy Feng, Sophie Bittinger, Michael Quinn, Deborah Neesham, Orla McNally
OBJECTIVE: Uterine papillary serous carcinoma (UPSC) is a rare variant of endometrial carcinoma responsible for up to 40% of endometrial cancer deaths. Controversy remains regarding optimal adjuvant therapy for UPSC, with lack of randomized trials to date. The objective of this retrospective study was to evaluate clinicopathological factors and determine event-free survival and overall survival (OS) in patients with UPSC managed within a single institution. MATERIALS AND METHODS: Medical and pathological records between 1987 and 2004 were reviewed at the Royal Women's Hospital, Melbourne, Australia...
January 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/26537059/survival-advantage-associated-with-multimodal-therapy-in-women-with-node-positive-stage-iiic-uterine-papillary-serous-carcinoma-a-national-cancer-database-study
#16
J F Lin, K Muñiz, P Sukumvanich, P Gehrig, S Beriwal, J L Kelley, R P Edwards, A B Olawaiye
OBJECTIVE: Uterine papillary serous carcinoma (UPSC) is an aggressive subtype of endometrial cancer. Adjuvant chemotherapy (CT) has become standard care in treatment of women with advanced-stage UPSC, but the role of consolidative radiotherapy (RT) is unclear. This study aims to evaluate survival outcomes of multimodal therapy. DESIGN: Retrospective cohort study using a National Cancer Database (NCDB). SETTING: United States of America. SAMPLE: A total of 1816 women diagnosed with UPSC...
October 2016: BJOG: An International Journal of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/26476418/extent-of-lymph-node-dissection-and-overall-survival-in-patients-with-uterine-carcinosarcoma-papillary-serous-and-endometrioid-adenocarcinoma-a-retrospective-cohort-study
#17
Ioannis Alagkiozidis, Jeremy Weedon, Allison Grossman, Pengfei Wang, Benjamin Mize, Kirstie Wilson, Tana Shah, Katherine Economos, Ghadir Salame, Ovadia Abulafia, Yi-Chun Lee
OBJECTIVE: To evaluate the interaction between extent of lymph node dissection (LND) and overall survival (OS) in patients with various histologic types of uterine cancer. METHODS: We retrospectively identified 834 patients who had primary surgery in our institution for uterine carcinosarcoma (CS), papillary serous (UPSC) and endometrioid adenocarcinoma between 1984 and 2009. Stage, grade, total lymph node count (LNC), positive LNC, adjuvant therapy, age, race and OS were collected...
December 2015: International Journal of Surgery
https://www.readbyqxmd.com/read/26272866/solitomab-an-epcam-cd3-bispecific-antibody-construct-bite-is-highly-active-against-primary-uterine-serous-papillary-carcinoma-cell-lines-in%C3%A2-vitro
#18
Stefania Bellone, Jonathan Black, Diana P English, Carlton L Schwab, Salvatore Lopez, Emiliano Cocco, Elena Bonazzoli, Federica Predolini, Francesca Ferrari, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E Schwartz, Alessandro D Santin
BACKGROUND: Uterine serous carcinoma is an aggressive form of endometrial cancer that carries an extremely poor prognosis. Solitomab is a novel bispecific single-chain antibody construct that targets epithelial cell adhesion molecule on tumor cells and also contains a CD3 binding region. We evaluated the expression levels of epithelial cell adhesion molecule and the in vitro activity of solitomab against primary uterine serous carcinoma cell lines in vitro and ex-vivo in the ascites of patients with uterine serous carcinoma...
January 2016: American Journal of Obstetrics and Gynecology
https://www.readbyqxmd.com/read/26235227/uterine-papillary-serous-carcinoma-pre-operatively-diagnosed-as-endometrioid-carcinoma-is-omentectomy-necessary
#19
Yoav Peled, Amir Aviram, Haim Krissi, Assaf Gershoni, Gad Sabah, Hanoch Levavi, Ram Eitan
BACKGROUND: Uterine papillary serous carcinoma (UPSC) is a relatively rare but aggressive uterine malignancy comprising approximately 10% of endometrial cancers. Many women pre-operatively misdiagnosed as having endometrioid carcinoma have ultimately UPSC on final pathology. These women receive inadequate surgical staging without omentectomy. AIM: To assess the value of omentectomy on disease-free interval and overall survival in women with UPSC who had an initial diagnosis of endometrioid carcinoma...
October 2015: Australian & New Zealand Journal of Obstetrics & Gynaecology
https://www.readbyqxmd.com/read/26060409/value-of-detection-of-serum-human-epididymis-secretory-protein-4-and-carbohydrate-antigen-125-in-diagnosis-of-early-endometrial-cancer-of-different-pathological-subtypes
#20
Xingui Liu, Fengting Zhao, Linli Hu, Yingpu Sun
This study explored the value of detection of human epididymis secretory protein 4 (HE4) and carbohydrate antigen 125 (CA125) from serum in diagnosis of early endometrial cancer of different pathological subtypes and discussed the mechanism of HE4 and CA125 in diagnosis. In this study, enzyme-linked immunosorbent assay and chemiluminescent immunoassay were used to detect HE4 and CA125 from serum in endometrial cancer and control groups. Besides, the concentration of HE4 and CA125 was compared in these two groups, and the expression of CA125 and HE4 and clinicopathological characteristics in patients with endometrial cancer were also analyzed...
2015: OncoTargets and Therapy
keyword
keyword
16782
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"